Phenylethylamine (PEA) 500mg - 100 capsules

Phenylethylamine (PEA) is an organic compound found naturally in the brain and also in certain foods, such as chocolate. It is a biogenic amine and a neurotransmitter. It has been investigated in the context of its potential to improve mood and attention.

Why is it considered a nootropic? It is considered a nootropic because it can influence brain activity, particularly the release of certain neurotransmitters such as dopamine and norepinephrine. This can result in improvements in attention, mood, and focus.

Mechanism of action: PEA functions as a neurotransmitter in the brain. It is a direct precursor to dopamine and norepinephrine, meaning it can increase the release of these neurotransmitters in the brain. By doing so, it is believed to produce stimulating effects and mood improvements.

Benefits of Phenylethylamine (PEA):

1. Improved mood and emotional well-being:
   • Natural Antidepressant: By stimulating the release of dopamine and serotonin, key neurotransmitters associated with pleasure, reward, and mood regulation, PEA may offer a boost in mood and help combat feelings of sadness or apathy.
   • Mood Elevation: PEA has been reported to induce a feeling of euphoria, similar to what people experience during the "honeymoon" in romantic relationships. In fact, it is believed that natural levels of PEA in the brain increase during the early stages of falling in love.
2. Cognitive stimulation:
   • Increased concentration and alertness: By enhancing the release of excitatory neurotransmitters, PEA can help improve concentration, especially on tasks that require sustained attention.
   • Improved mental clarity: May reduce the feeling of "brain fog", making people feel more mentally clear and alert.
3. Aphrodisiac effect:
   • Libido stimulation: PEA, by influencing dopamine and other neurotransmitters related to pleasure and reward, can enhance libido and increase sexual interest.
   • Improved sexual satisfaction: In addition to increasing desire, there are indications that PEA may improve overall satisfaction during intimate relationships.
4. Weight and appetite control:
   • Appetite suppression: PEA can affect the appetite centers in the brain, leading to a faster feeling of fullness and a reduction in caloric intake.
   • Increased metabolism: There is evidence to suggest that PEA may increase metabolic rate, which could aid in weight loss.
5. Neuroprotective effects:
   • Neuronal protection: It has been proposed that PEA has antioxidant properties that may protect brain cells from oxidative damage, which is a factor in brain aging and neurodegenerative diseases.
6. Improved creativity and cognitive flow:
   • Promoting creative thinking: There are anecdotal reports suggesting that PEA can release cognitive barriers, allowing greater exploration of creative ideas and thoughts.
   • “Flow” state: By improving the connection between different areas of the brain, PEA may facilitate “flow” or “zone” states, where a person feels completely immersed and focused on a particular activity.
7. Fatigue reduction:
   • Increased energy: Given its stimulating effect, PEA can help combat fatigue and increase endurance, both mentally and physically.
8. Improved stress response:
   • Cortisol regulation: It has been suggested that PEA may influence the way the body responds to stress, potentially modulating the release of cortisol, the "stress hormone."

Remember, although these benefits are associated with phenylethylamine, the response may vary between individuals and not everyone will experience all of these effects to the same magnitude. It is crucial to consider dosages and interactions with other supplements or medications before you start using PEA. It is always advisable to consult a health professional before starting any supplement.

Absorption: PEA is rapidly absorbed from the gastrointestinal tract and can cross the blood-brain barrier to affect brain activity. However, it is metabolized very quickly by the enzyme monoamine oxidase B (MAO-B), which means that it has a very short half-life. To improve its absorption and prolong its effects, it is often taken together with MAO-B inhibitors.

Adverse effects and contraindications: Side effects of PEA may include anxiety, agitation, elevated blood pressure, and rapid heart rate. Due to its effect on neurotransmitters, PEA may interact with antidepressant medications and other medications that affect neurotransmitter activity. Those with heart or blood pressure disorders, as well as those on antidepressant medications or MAOIs, should consult a doctor before taking PEA.

Note: It is important to remember that although nootropics may offer cognitive and mood-related benefits, they should not be considered a substitute for proper medical care.

More information about PEA and its dosage: https://nootropicsexpert.com/phenylethylamine/

References on studies:

[Yo] Janssen PA, Leysen JE, Megens AA, Awouters FH “Does phenylethylamine act as an endogenous amphetamine in some patients?” International Journal of Neuropsychopharmacology . 1999 Sep;2(3):229-240. ( source )

[ii] Miller GM “The Emerging Role of Trace Amine Associated Receptor 1 in the Functional Regulation of Monoamine Transporters and Dopaminergic Activity” Journal of Neurochemistry 2011 Jan; 116(2): 164–176. ( source )

[iii] Granvogl M., Bugan S., Schieberle P. “Formation of amines and aldehydes from parent amino acids during thermal processing of cocoa and model systems: new insights into pathways of the strecker reaction.” Journal of Agricultural and Food Chemistry . 2006 Mar 8; 54(5):1730-9. ( source )

[iv] Khan MZ, Nawaz W. “The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system.” Biomedicine and Pharmacotherapy . 2016 Oct;83:439-449. ( source )

[v] Shannon HE, Cone EJ, Yousefnejad D. “Physiologic effects and plasma kinetics of beta-phenylethylamine and its N-methyl homolog in the dog.” Journal of Pharmacology and Experimental Therapeutics . 1982 Oct;223(1):190-6. ( source )

[saw] Sabelli HC, Javaid JI “Phenylethylamine modulation of affect: therapeutic and diagnostic implications.” Journal of Neuropsychiatry and Clinical Neuroscience . 1995 Winter;7(1):6-14. ( source )

[vii] Sabelli H., Fink P., Fawcett J., Tom C. “Sustained antidepressant effect of PEA replacement.” Journal of Neuropsychiatry and Clinical Neuroscience . 1996 Spring;8(2):168-71. ( source )

[viii] Shimazu S., Miklya I. “Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.” Progress in Neuropsychopharmacological and Biological Psychiatry . 2004 May;28(3):421-7. ( source )

[ix] Xie Z., Miller.GM. “Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain.” Journal of Pharmacology & Experimental Therapeutics 2008 May;325(2):617-28. doi: 10.1124/jpet.107.134247. ( source )

[x] Benzenhöfer U., Passie T. “Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin.” Addiction . 2010 Aug;105(8):1355-61. ( source )

[xi] Bunzow JR et. to the. “Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor .” Molecular Pharmacology . 2001 Dec;60(6):1181-8. ( source )

[xii] World Health Association WHO. “The global burden of disease: 2004 update.” WHO Library Cataloguing-in-Publication Data; 2008. ISBN 978 92 4 156371 0.

[xiii] Xie Z., Miller GM “Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain” Journal of Pharmacology & Experimental Therapeutics 2008 May;325(2):617-28. ( source )

[xiv] Scassellati C., Bonvicini C., Faraone SV, Gennarelli M. “Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses.” Journal of the American Academy of Child Adolescent Psychiatry . 2012 Oct; 51(10):1003-1019. ( source )

[xv] Kusaga A., Yamashita Y., Koeda T., Hiratani M., Kaneko M., Yamada S., Matsuishi T. “Increased urine phenylethylamine after methylphenidate treatment in children with ADHD.” Annals of Neurology . 2002 Sep; 52(3):372-4. ( source )

[xvi] Xie Z., Miller GM “Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain.” Journal of Pharmacology & Experimental Therapeutics . 2008 May; 325(2):617-28. ( source )

[xvii] Shannon HE, Cone EJ, Yousefnejad D. “Physiologic effects and plasma kinetics of beta-phenylethylamine and its N-methyl homolog in the dog.” Journal of Pharmacology & Experimental Therapeutics . 1982 Oct; 223(1):190-6. ( source )

[xviii] Cashin CH “Effect of sympathomimetic drugs in eliciting hypertensive responses to reserpine in the rat, after pretreatment with monoamine oxidase inhibitors.” British Journal of Pharmacology . 1972 Feb;44(2):203-9. ( source )

[xix] Finberg JP, Gillman K. “Selective inhibitors of monoamine oxidase type B and the "cheese effect".” International Review of Neurobiology . 2011;100:169-90. ( source )

[xx] Zarmouth NO, et. to the. “Natural Products Screening for the Identification of Selective Monoamine Oxidase-B Inhibitors” European Journal of Medicinal Plants 2016 May; 15(1): 14802. ( source )